(Q36689000)

15 August 2017

1 reference

title

RTS,S/AS02A for malaria (English)

1 reference

15 August 2017

0 references

Kalifa A Bojang

1

0 references

publication date

1 October 2006

1 reference

Expert Review of Vaccines

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

611-615

1 reference

15 August 2017

5

1 reference

Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT).

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

The economic and social burden of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Pre-erythrocytic malaria vaccines: towards greater efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Structure of the Gene Encoding the Immunodominant Surface Antigen on the Sporozoite of the Human Malaria Parasite Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Fine specificities of monoclonal antibodies against the Plasmodium falciparum circumsporozoite protein: recognition of both repetitive and non-repetitive regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.5.611

21 January 2018

Identifiers

DOI

10.1586/14760584.5.5.611

1 reference

15 August 2017

1 reference

PubMed ID

17181435